- Home
- CBOE vs RVMD Comparison
CBOE vs RVMD Comparison
Compare CBOE & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBOE | RVMD |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 40.3B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBOE | RVMD |
|---|---|---|
| Price | $333.74 | $191.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 25 |
| Target Price | ★ $331.40 | $258.84 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 10-30-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ 44.52 | N/A |
| EPS | ★ 7.01 | N/A |
| Revenue | ★ $2,229,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.22 | $526.64 |
| P/E Ratio | $44.67 | ★ N/A |
| Revenue Growth | ★ 239.31 | N/A |
| 52 Week Low | $227.15 | $56.66 |
| 52 Week High | $371.18 | $224.31 |
Technical Indicators
Market Signals| Indicator | CBOE | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 63.83 | 47.87 |
| Support Level | $273.63 | $188.18 |
| Resistance Level | $371.18 | $194.19 |
| Average True Range (ATR) | 11.27 | 8.20 |
| MACD | 1.35 | 0.44 |
| Stochastic Oscillator | 86.25 | 52.65 |
Price Performance
Historical ComparisonAbout CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.